secwatch.observer — SEC 8-K summary
======================================

Issuer:     IB Acquisition Corp. (IBAC)
CIK:        0001998781
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001493152-26-011110
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

GNQ Insilico enters collaboration with Fortune 100 tech firm for AI-driven drug discovery
--------------------------------------------------------------------------------

- GNQ Insilico signed a Joint Initiative Agreement with a Fortune 100 global technology company.
- Collaboration combines GNQ's AI platforms with partner's consulting, cloud, and quantum computing.
- Initial term of two years, global territory, non-exclusive, with option to extend.
- Partnership aims to advance AI-driven drug discovery and precision medicine solutions.
- Relates to proposed business combination between IB Acquisition Corp. (IBAC) and GNQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1998781/000149315226011110/0001493152-26-011110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1998781/000149315226011110/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-011110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer